Ophthalmology Therapeutics: Does current pipeline innovation hold the potential to affect the future ophthalmology market?

This Frontier Pharma: Ophthalmology Therapeutics assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products.

Pune, India - March 14, 2018 /MarketersMedia/ —

The pipeline is varied in terms of molecular targets and molecule types. Products acting on the immune system and neurotransmitter signaling are the most prevalent, but no single target dominates by any clear margin. There are a total of 194 first-in class pipeline products in development for ophthalmologic indications 38% of the 512 pipeline products for which there is a disclosed molecular target. Encompassing gene therapies, slowing of the visual cycle and antisense therapies, the pipeline appears robust and has huge potential to strengthen treatment options for ophthalmological disorders.

Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs

Reasons To Buy
• Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
• Visualize the composition of the ophthalmological disorders market in terms of dominant molecule types and targets, and understand the current unmet needs and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
• Analyze the ophthalmological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating ophthalmological disorders to overcome the overwhelming level of unmet need.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
• Identify commercial opportunities in the ophthalmological disorders deals landscape by analyzing trends in licensing and co-development deals, and a curated list of ophthalmological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Get this report at: https://www.themarketreports.com/report/buy-now/935550

In the past the ophthalmological disorders therapy area has suffered from a lack of full understanding of the pathophysiology and underlying mechanisms of the diseases. However, as this knowledge has improved vastly in recent years, potential targets have been identified for treatment. As well as the main disorders previously mentioned, there is also interest in developing treatments for indications such as allergic conjunctivitis and retinitis pigmentosa. The approval of a gene therapy for retinitis pigmentosa is indicative of this progress, and represents the first gene therapy approved for an inherited condition by the FDA.

Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935550

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/ophthalmology-therapeutics-does-current-pipeline-innovation-hold-the-potential-to-affect-the-future-ophthalmology-market/314326

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs%20%20

Source: MarketersMedia

Release ID: 314326

Latest News

The Latest: Prosecutor wants 5 to 10 years for Cosby

Sep 25, 2018

NORRISTOWN, Pa. — The Latest on Bill Cosby's sentencing hearing (all times local): 4:10 p.m. Prosecutors are asking a judge to sentence Bill Cosby to five to 10 years in prison for drugging and sexually assaulting a woman at his suburban Philadelphia home. Montgomery County District Attorney Kevin Steele said in court Monday that the 81-year-old comedian is still capable of slipping women drugs and assaulting them. He says the sentence should send the message to others that "nobody's above the law." Steele quoted from chief accuser Andrea Constand's victim-impact statement, which said the attack had crushed her spirit. Cosby's...

Pistons hope Jackson will be ready for opener

Sep 25, 2018

DETROIT — The Detroit Pistons have a new coach — and the usual amount of optimism that accompanies such a big change. What they really could use this season is a healthy point guard. The Pistons are hopeful Reggie Jackson will be ready to play by the start of the season, although he's still working his way back into shape following an ankle injury. Jackson went down in late December, derailing what had been a promising start for Detroit in 2017-18. Ed Stefanski, a new senior executive for the Pistons, sounds optimistic about Jackson's health, but the point guard's recovery...

Seattle Mariners' Felix Hernandez becomes US citizen

Sep 25, 2018

SEATTLE — Mariners teammates stood and applauded and "God Bless America" played on speakers when Felix Hernandez entered Seattle's clubhouse after becoming a U.S. citizen. A native of Venezuela, the 32-year-old pitcher passed his citizenship interview Monday and was among 74 people from 36 countries who became naturalized U.S. citizens during a ceremony in downtown Seattle. "This country has given me everything," Hernandez said. "It's a dream come true. It means a lot. We've been here a long time. I wanted to do it." Strife in Venezuela is among the reasons Hernandez desired U.S. citizenship. He wants to bring his...

Pelicans' Davis keeps focus short-term, deflects speculation

Sep 25, 2018

METAIRIE, La. — Anthony Davis swatted away the notion that his decision to hire new representation meant he was setting the stage for a change of scenery. With three seasons left on his contract and five All-Star nods to his name, Davis' leverage to control where he plays is growing. So when he recently left the Wasserman agency that negotiated his current contract and joined Klutch Sports, which also represents Los Angeles Lakers star LeBron James, it begged questions about the reasons for the switch. The move also stoked paranoia in New Orleans, the city Chris Paul left in his...

LeBron 'humbled' to join Lakers, expects 'something special'

Sep 25, 2018

EL SEGUNDO, Calif. — LeBron James realizes the size of the challenge he accepted when he joined the Los Angeles Lakers. After eight consecutive NBA Finals appearances, he knows his new team isn't a true contender with Golden State and the NBA's elite just yet. The superstar welcomed every step in the process Monday as he began his next chapter in purple and gold. James finally made his first formal appearance as a member of the Lakers at their media day, nearly three months after he left Cleveland for a four-year, $153.3 million free-agent deal. In between posing for photos...

About Us

The Final Scoreboard has fast, accurate live scores for you. We provide premium online content from in-depth analysis to the scores and statistics across American and European Sports.

Contact us: sales[at]thefinalscoreboard.com

Subscribe Now!